Enzymotec, a research-based biotechnology company, has announced positive results from clinical trials of its lipid-based ingredient line for infant nutrition.
The large-scale clinical trials were conducted on newborn term infants in several institutes worldwide.
The trials are part of the company’s strategy to develop and market a product line imitating the fundamental lipids such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA) found in mother’s milk.
Enzymotec Infant Nutrition R&D director Dr Yael Lifshitz said the clinical trials plan represents the company’s commitment to researching human milk.
"We developed this innovative ingredient and educated the premium infant formula market over the last several years," Lifshitz said.
"Enzymotec invested 10% of its revenue in research and development – a percentage considered among the highest in the industry."
Enzymotec conducted a clinical trial on InFat; a beta-palmitate ingredient that mimics the fat composition and properties of human milk fat, which allows easy digestion and optimised uptake of calcium, fat recovery and energy.
The study was conducted by Professor Chen Yu-Ming, the principle investigator at Sun Yat-Sen University and in collaboration with Enzymotec.
Advanced Lipids, a joint venture of AAK and Enzymotec, is marketing InFat.
Image: Enzymotec completed study on health benefits of InFat. Photo: Enzymotec.